vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and Opendoor Technologies Inc. (OPEN). Click either name above to swap in a different company.

Opendoor Technologies Inc. is the larger business by last-quarter revenue ($736.0M vs $406.6M, roughly 1.8× BIOCRYST PHARMACEUTICALS INC). BIOCRYST PHARMACEUTICALS INC runs the higher net margin — 60.5% vs -148.9%, a 209.4% gap on every dollar of revenue. On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (209.1% vs -32.1%). BIOCRYST PHARMACEUTICALS INC produced more free cash flow last quarter ($291.2M vs $67.0M). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (109.4% CAGR vs -21.1%).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

Opendoor Technologies Inc. is an online company that buys and sells residential real estate. Headquartered in San Francisco, it makes instant cash offers on homes through an online process, makes repairs on the properties it purchases and re-lists them for sale. It also provides mobile application-based home buying services along with financing. As of November 2021, the company operates in 44 markets in the US.

BCRX vs OPEN — Head-to-Head

Bigger by revenue
OPEN
OPEN
1.8× larger
OPEN
$736.0M
$406.6M
BCRX
Growing faster (revenue YoY)
BCRX
BCRX
+241.2% gap
BCRX
209.1%
-32.1%
OPEN
Higher net margin
BCRX
BCRX
209.4% more per $
BCRX
60.5%
-148.9%
OPEN
More free cash flow
BCRX
BCRX
$224.2M more FCF
BCRX
$291.2M
$67.0M
OPEN
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
109.4%
-21.1%
OPEN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BCRX
BCRX
OPEN
OPEN
Revenue
$406.6M
$736.0M
Net Profit
$245.8M
$-1.1B
Gross Margin
97.7%
7.7%
Operating Margin
64.0%
-20.4%
Net Margin
60.5%
-148.9%
Revenue YoY
209.1%
-32.1%
Net Profit YoY
1017.5%
-869.9%
EPS (diluted)
$1.13
$-1.42

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
OPEN
OPEN
Q4 25
$406.6M
$736.0M
Q3 25
$159.4M
$915.0M
Q2 25
$163.4M
$1.6B
Q1 25
$145.5M
$1.2B
Q4 24
$131.5M
$1.1B
Q3 24
$117.1M
$1.4B
Q2 24
$109.3M
$1.5B
Q1 24
$92.8M
$1.2B
Net Profit
BCRX
BCRX
OPEN
OPEN
Q4 25
$245.8M
$-1.1B
Q3 25
$12.9M
$-90.0M
Q2 25
$5.1M
$-29.0M
Q1 25
$32.0K
$-85.0M
Q4 24
$-26.8M
$-113.0M
Q3 24
$-14.0M
$-78.0M
Q2 24
$-12.7M
$-92.0M
Q1 24
$-35.4M
$-109.0M
Gross Margin
BCRX
BCRX
OPEN
OPEN
Q4 25
97.7%
7.7%
Q3 25
98.6%
7.2%
Q2 25
98.3%
8.2%
Q1 25
96.9%
8.6%
Q4 24
95.4%
7.8%
Q3 24
97.3%
7.6%
Q2 24
98.4%
8.5%
Q1 24
98.6%
9.7%
Operating Margin
BCRX
BCRX
OPEN
OPEN
Q4 25
64.0%
-20.4%
Q3 25
18.6%
-7.4%
Q2 25
18.2%
-0.8%
Q1 25
14.6%
-4.9%
Q4 24
-3.4%
-8.7%
Q3 24
6.6%
-4.9%
Q2 24
8.0%
-4.8%
Q1 24
-15.6%
-7.4%
Net Margin
BCRX
BCRX
OPEN
OPEN
Q4 25
60.5%
-148.9%
Q3 25
8.1%
-9.8%
Q2 25
3.1%
-1.9%
Q1 25
0.0%
-7.4%
Q4 24
-20.4%
-10.4%
Q3 24
-12.0%
-5.7%
Q2 24
-11.6%
-6.1%
Q1 24
-38.1%
-9.2%
EPS (diluted)
BCRX
BCRX
OPEN
OPEN
Q4 25
$1.13
$-1.42
Q3 25
$0.06
$-0.12
Q2 25
$0.02
$-0.04
Q1 25
$0.00
$-0.12
Q4 24
$-0.13
$-0.16
Q3 24
$-0.07
$-0.11
Q2 24
$-0.06
$-0.13
Q1 24
$-0.17
$-0.16

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
OPEN
OPEN
Cash + ST InvestmentsLiquidity on hand
$274.7M
$962.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$-119.2M
$1.0B
Total Assets
$514.2M
$2.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
OPEN
OPEN
Q4 25
$274.7M
$962.0M
Q3 25
$212.9M
$962.0M
Q2 25
$260.0M
$789.0M
Q1 25
$295.1M
$559.0M
Q4 24
$320.9M
$679.0M
Q3 24
$96.8M
$837.0M
Q2 24
$78.4M
$809.0M
Q1 24
$84.3M
$990.0M
Stockholders' Equity
BCRX
BCRX
OPEN
OPEN
Q4 25
$-119.2M
$1.0B
Q3 25
$-387.9M
$811.0M
Q2 25
$-421.6M
$631.0M
Q1 25
$-451.9M
$645.0M
Q4 24
$-475.9M
$713.0M
Q3 24
$-468.6M
$801.0M
Q2 24
$-475.6M
$845.0M
Q1 24
$-476.2M
$899.0M
Total Assets
BCRX
BCRX
OPEN
OPEN
Q4 25
$514.2M
$2.4B
Q3 25
$446.4M
$2.7B
Q2 25
$457.2M
$2.9B
Q1 25
$480.0M
$3.3B
Q4 24
$490.4M
$3.1B
Q3 24
$491.3M
$3.4B
Q2 24
$472.4M
$3.4B
Q1 24
$467.9M
$3.4B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCRX
BCRX
OPEN
OPEN
Operating Cash FlowLast quarter
$292.0M
$70.0M
Free Cash FlowOCF − Capex
$291.2M
$67.0M
FCF MarginFCF / Revenue
71.6%
9.1%
Capex IntensityCapex / Revenue
0.2%
0.4%
Cash ConversionOCF / Net Profit
1.19×
TTM Free Cash FlowTrailing 4 quarters
$344.9M
$1.0B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCRX
BCRX
OPEN
OPEN
Q4 25
$292.0M
$70.0M
Q3 25
$41.6M
$435.0M
Q2 25
$41.3M
$823.0M
Q1 25
$-27.5M
$-279.0M
Q4 24
$-5.2M
$-80.0M
Q3 24
$8.2M
$62.0M
Q2 24
$-1.4M
$-399.0M
Q1 24
$-53.7M
$-178.0M
Free Cash Flow
BCRX
BCRX
OPEN
OPEN
Q4 25
$291.2M
$67.0M
Q3 25
$40.3M
$432.0M
Q2 25
$41.1M
$821.0M
Q1 25
$-27.7M
$-283.0M
Q4 24
$-5.9M
$-83.0M
Q3 24
$8.2M
$56.0M
Q2 24
$-1.5M
$-407.0M
Q1 24
$-53.9M
$-186.0M
FCF Margin
BCRX
BCRX
OPEN
OPEN
Q4 25
71.6%
9.1%
Q3 25
25.3%
47.2%
Q2 25
25.2%
52.4%
Q1 25
-19.0%
-24.5%
Q4 24
-4.5%
-7.7%
Q3 24
7.0%
4.1%
Q2 24
-1.4%
-26.9%
Q1 24
-58.1%
-15.7%
Capex Intensity
BCRX
BCRX
OPEN
OPEN
Q4 25
0.2%
0.4%
Q3 25
0.8%
0.3%
Q2 25
0.1%
0.1%
Q1 25
0.1%
0.3%
Q4 24
0.5%
0.3%
Q3 24
0.1%
0.4%
Q2 24
0.1%
0.5%
Q1 24
0.3%
0.7%
Cash Conversion
BCRX
BCRX
OPEN
OPEN
Q4 25
1.19×
Q3 25
3.23×
Q2 25
8.12×
Q1 25
-859.91×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons